CN115814022B - Traditional Chinese medicine composition, preparation method thereof and application thereof in preparation of medicine with function of preventing and/or treating asthma - Google Patents
Traditional Chinese medicine composition, preparation method thereof and application thereof in preparation of medicine with function of preventing and/or treating asthma Download PDFInfo
- Publication number
- CN115814022B CN115814022B CN202211594355.9A CN202211594355A CN115814022B CN 115814022 B CN115814022 B CN 115814022B CN 202211594355 A CN202211594355 A CN 202211594355A CN 115814022 B CN115814022 B CN 115814022B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 208000006673 asthma Diseases 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 20
- 241000756943 Codonopsis Species 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 244000044554 Elaeagnus pungens Species 0.000 claims description 29
- 235000013935 Elaeagnus pungens Nutrition 0.000 claims description 29
- 241000132012 Atractylodes Species 0.000 claims description 19
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 claims description 19
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 19
- 241000096284 Gynochthodes officinalis Species 0.000 claims description 19
- 244000248021 Vitex negundo Species 0.000 claims description 19
- 235000013427 Vitex negundo var incisa Nutrition 0.000 claims description 19
- 235000014961 Vitex negundo var negundo Nutrition 0.000 claims description 19
- 235000013399 edible fruits Nutrition 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 19
- 235000014956 negundo chastetree Nutrition 0.000 claims description 19
- 240000000249 Morus alba Species 0.000 claims description 18
- 235000008708 Morus alba Nutrition 0.000 claims description 18
- 240000002948 Ophiopogon intermedius Species 0.000 claims description 18
- 241000405414 Rehmannia Species 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 241001061264 Astragalus Species 0.000 claims description 15
- 240000003377 Shepherdia canadensis Species 0.000 claims description 15
- 235000018324 Shepherdia canadensis Nutrition 0.000 claims description 15
- 235000006533 astragalus Nutrition 0.000 claims description 15
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 claims description 15
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims description 15
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 15
- 239000011347 resin Substances 0.000 claims description 15
- 229920005989 resin Polymers 0.000 claims description 15
- 229930182490 saponin Natural products 0.000 claims description 15
- 150000007949 saponins Chemical class 0.000 claims description 15
- 210000004233 talus Anatomy 0.000 claims description 15
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 14
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 14
- 229940010454 licorice Drugs 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 12
- 239000012535 impurity Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 9
- 239000010931 gold Substances 0.000 claims description 9
- 229910052737 gold Inorganic materials 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 241000007126 Codonopsis pilosula Species 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- 230000008901 benefit Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000009636 Huang Qi Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 23
- 244000303040 Glycyrrhiza glabra Species 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 16
- 230000036387 respiratory rate Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 238000010828 elution Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 5
- 235000011477 liquorice Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 241000893536 Epimedium Species 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 229940107666 astragalus root Drugs 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 235000018905 epimedium Nutrition 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241001522129 Pinellia Species 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- -1 smoking Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Abstract
The invention relates to the technical field of traditional Chinese medicines, and in particular discloses a traditional Chinese medicine composition, a preparation method thereof and application thereof in preparing medicines with an effect of preventing and/or treating asthma. The traditional Chinese medicine composition comprises the following raw material components: herba Epimedii, radix Morindae officinalis, radix rehmanniae Preparata, rhizoma Polygonati, radix Ophiopogonis, radix astragali, radix Codonopsis, atractylodis rhizoma, fructus Vitics Simplicifoliae, cortex Mori, rhizoma Pinelliae Preparata, fructus Citri Sarcodactylis, and Glycyrrhrizae radix. Further, the composition also comprises radix seu folium Bubali and folium Elaeagni. The traditional Chinese medicine composition prepared from the traditional Chinese medicine raw material components has better effect of preventing and treating asthma; in addition, the traditional Chinese medicine composition has the advantages of fine prescription of the raw materials, no valuable medicine or toxic medicine, safety, reliability, low technical risk, wide market demand and obvious economic and social benefits.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition, a preparation method thereof and application thereof in preparing medicines with an effect of preventing and/or treating asthma.
Background
Bronchial asthma is a common asthma, a heterogeneous disease characterized by chronic inflammation of the airways involving various cells (e.g. eosinophils, mast cells, T lymphocytes, neutrophils, airway epithelial cells, etc.) and cellular components. The clinical symptoms are usually recurrent wheezing, shortness of breath, chest distress and/or cough. There are many factors that induce asthma, such as air pollution, smoking, respiratory tract infection, inhalation of cold air, distilled water droplets, etc., which can induce asthma attacks.
Currently, the common drugs for treating asthma are western medicines such as beclomethasone, budesonide, fluticasone, mometasone and the like. Therefore, the development of a traditional Chinese medicine composition with the function of treating asthma, in particular to a traditional Chinese medicine composition with the excellent function of treating asthma, which has important application value.
Disclosure of Invention
In order to overcome at least one technical problem existing in the prior art, the invention provides a traditional Chinese medicine composition.
The technical problems to be solved by the invention are realized by the following technical scheme:
A Chinese medicinal composition comprises the following raw material components: herba Epimedii, radix Morindae officinalis, radix rehmanniae Preparata, rhizoma Polygonati, radix Ophiopogonis, radix astragali, radix Codonopsis, atractylodis rhizoma, fructus Vitics Simplicifoliae, cortex Mori, rhizoma Pinelliae Preparata, fructus Citri Sarcodactylis, and Glycyrrhrizae radix.
The inventor finds that the traditional Chinese medicine composition prepared from the traditional Chinese medicine raw material components has better effect of preventing and treating asthma in a large amount of experimental researches; in addition, the traditional Chinese medicine composition has the advantages of fine prescription of the raw materials, no valuable medicine or toxic medicine, safety, reliability, low technical risk, wide market demand and obvious economic and social benefits.
Preferably, the traditional Chinese medicine composition comprises the following raw material components in parts by weight: 50-80 parts of herba epimedii; 30-50 parts of morinda officinalis; 30-50 parts of prepared rehmannia root; 20-30 parts of rhizoma polygonati; 5-10 parts of dwarf lilyturf tuber; 5-10 parts of astragalus; 3-5 parts of codonopsis pilosula; 5-10 parts of bighead atractylodes rhizome; 3-5 parts of negundo chastetree fruit; 15-20 parts of white mulberry root-bark; 10-15 parts of rhizoma pinellinae praeparata; 5-10 parts of fingered citron; 30-50 parts of raw licorice.
Further preferably, the traditional Chinese medicine composition comprises the following raw material components in parts by weight: 60-70 parts of herba epimedii; 40-50 parts of morinda officinalis; 40-50 parts of prepared rehmannia root; 25-30 parts of rhizoma polygonati; 8-10 parts of dwarf lilyturf tuber; 5-8 parts of astragalus; 3-4 parts of codonopsis pilosula; 5-8 parts of bighead atractylodes rhizome; 4-5 parts of negundo chastetree fruit; 15-18 parts of white mulberry root-bark; 10-12 parts of rhizoma pinellinae praeparata; 5-8 parts of fingered citron; 40-50 parts of raw licorice.
Most preferably, the traditional Chinese medicine composition comprises the following raw material components in parts by weight: 70 parts of herba epimedii; 40 parts of morinda officinalis; 40 parts of prepared rehmannia root; 25 parts of rhizoma polygonati; 8 parts of dwarf lilyturf tuber; 8 parts of astragalus; 4 parts of radix codonopsis; 8 parts of bighead atractylodes rhizome; 4 parts of negundo chastetree fruit; 18 parts of white mulberry root-bark; 12 parts of rhizoma pinellinae praeparata; 8 parts of fingered citron; 40 parts of raw licorice.
Preferably, the composition further comprises leaf of Elaeagnus pungens and Elaeagnus pungens.
The inventor further and surprisingly found in the research that the traditional Chinese medicine composition raw materials comprising epimedium herb, morinda officinalis, prepared rehmannia root, rhizoma polygonati, dwarf lilyturf tuber, astragalus root, dangshen, bighead atractylodes rhizome, negundo chastetree fruit, white mulberry root-bark, rhizoma pinellinae praeparata, fingered citron and raw liquorice are further added with the leaf of elaeagnus pungens, so that the asthma treatment effect of the prepared traditional Chinese medicine composition can be remarkably improved.
Further preferably, the parts by weight of the leaf of elaeagnus pungens and the leaf of elaeagnus pungens in the composition are respectively: unlocking 20-30 parts of a gold lock; 20-30 parts of elaeagnus pungens leaf.
Most preferably, the parts by weight of the leaf of elaeagnus pungens and the leaf of elaeagnus pungens in the composition are respectively: unlocking 25 parts of a gold lock; 25 parts of elaeagnus pungens leaf.
The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps:
(1) Mixing the Chinese medicinal materials, adding water, and heating to extract to obtain extractive solution;
(2) Concentrating the extractive solution under reduced pressure to remove water, and drying to obtain Chinese medicinal extract.
Preferably, the extraction in the step (1) means that the heating reflux extraction is carried out at 80-100 ℃ for 1-2 h.
Preferably, the weight ratio of water to the traditional Chinese medicine raw materials in the step (1) is 5-15:1.
Most preferably, the weight ratio of water to the traditional Chinese medicine raw materials in the step (1) is 10:1.
Preferably, the traditional Chinese medicine raw materials in the step (1) are herba epimedii, morinda officinalis, prepared yellow, rhizoma polygonati, dwarf lilyturf tuber, astragalus, dangshen, bighead atractylodes rhizome, negundo chastetree fruit, white mulberry root-bark, rhizoma pinellinae praeparata, fingered citron and raw liquorice.
Preferably, the traditional Chinese medicine raw materials in the step (1) are herba epimedii, morinda officinalis, prepared yellow, rhizoma polygonati, radix polygonati officinalis, thorn leaves, radix ophiopogonis, radix astragali, radix codonopsis, bighead atractylodes rhizome, fructus negundo chastetree fruit, cortex mori, rhizoma pinellinae praeparata, fingered citron and raw liquorice.
Preferably, the water in step (1) is an aqueous solution containing soapberry saponin and n-octyl-beta-D-glucopyranoside.
Further preferably, the mass fraction of soapberry saponin and n-octyl-beta-D-glucopyranoside in water is 0.1 to 1 percent respectively.
Most preferably, the mass fraction of soapberry saponin and n-octyl-beta-D-glucopyranoside in water is 0.3% respectively.
The inventors have further surprisingly found in the study that the use of the aqueous solution containing soapberry saponin and n-octyl-beta-D-glucopyranoside for the preparation of a traditional Chinese medicine composition can further improve the asthma treatment effect of the prepared traditional Chinese medicine composition compared with the traditional Chinese medicine composition prepared by the pure water extraction.
Preferably, the water extract of the traditional Chinese medicine is further put on a macroporous resin column, and the impurities are removed by eluting with 15 to 20 percent of ethanol; then eluting with 30-35% ethanol, collecting the eluent eluted with 30-35% ethanol, concentrating under reduced pressure, and drying to obtain the traditional Chinese medicine composition.
The inventor further and surprisingly found in the research that the effect of treating asthma is further greatly improved by further preparing the traditional Chinese medicine water extract by macroporous resin column chromatography.
For macroporous resin column chromatography, the inventor needs to say that the elution condition of macroporous resin is very critical; the inventor has surprisingly found that compared with the traditional Chinese medicine water extract, the traditional Chinese medicine composition prepared by eluting the traditional Chinese medicine water extract with 15-20% of ethanol to remove impurities and then eluting with 30-35% of ethanol can further and greatly improve the asthma treatment effect; compared with the traditional Chinese medicine water extract, the traditional Chinese medicine composition obtained under other macroporous resin elution conditions has the advantage that the asthma treatment effect is not necessarily improved or is further improved greatly.
In the present invention, the above-mentioned 15 to 20% ethanol and 30 to 35% ethanol specifically means an aqueous ethanol solution having a volume fraction of 15 to 20% and an aqueous ethanol solution having a volume fraction of 30 to 35%.
The method provides the application of the traditional Chinese medicine composition in preparing medicines with the function of preventing and/or treating asthma.
Preferably, the asthma is bronchial asthma.
Preferably, the medicament is in the form of granules, spray, oral liquid, powder, tablets or capsules.
The beneficial effects are that: the invention provides a Chinese medicinal composition with brand new composition; the traditional Chinese medicine composition prepared from the traditional Chinese medicine raw material components has better effect of preventing and treating asthma; in addition, the traditional Chinese medicine composition has the advantages of fine prescription of the raw materials, no valuable medicine or toxic medicine, safety, reliability, low technical risk, wide market demand and obvious economic and social benefits.
The traditional Chinese medicine composition has the effect of treating asthma; therefore, the active ingredient of the compound has important application prospect in preparing medicines with the functions of preventing and treating asthma.
Detailed Description
The present invention is further explained below with reference to examples, which are not intended to limit the present invention in any way.
EXAMPLE 1 preparation of a Chinese medicinal composition
The raw materials comprise the following components in parts by weight: 70 parts of herba epimedii; 40 parts of morinda officinalis; 40 parts of prepared rehmannia root; 25 parts of rhizoma polygonati; 8 parts of dwarf lilyturf tuber; 8 parts of astragalus; 4 parts of radix codonopsis; 8 parts of bighead atractylodes rhizome; 4 parts of negundo chastetree fruit; 18 parts of white mulberry root-bark; 12 parts of rhizoma pinellinae praeparata; 8 parts of fingered citron; 40 parts of raw licorice.
The preparation method comprises the following steps:
(1) Mixing the above Chinese medicinal materials, adding 10 times of water, and reflux extracting at 100deg.C for 1.5 hr to obtain extractive solution;
(2) Concentrating the extractive solution under reduced pressure to remove water, and drying to obtain Chinese medicinal extract.
EXAMPLE 2 preparation of a Chinese medicinal composition
The raw materials comprise the following components in parts by weight: 70 parts of herba epimedii; 40 parts of morinda officinalis; 40 parts of prepared rehmannia root; 25 parts of rhizoma polygonati; unlocking 25 parts of a gold lock; 25 parts of elaeagnus pungens leaf; 8 parts of dwarf lilyturf tuber; 8 parts of astragalus; 4 parts of radix codonopsis; 8 parts of bighead atractylodes rhizome; 4 parts of negundo chastetree fruit; 18 parts of white mulberry root-bark; 12 parts of rhizoma pinellinae praeparata; 8 parts of fingered citron; 40 parts of raw licorice.
The preparation method is the same as in example 1.
Example 2 is different from example 1 in that example 2 is added with a combination of a leaf of Elaeagnus pungens and a leaf of Elaeagnus pungens in the raw materials of the Chinese medicinal composition as compared with example 1.
EXAMPLE 3 preparation of a Chinese medicinal composition
The raw materials comprise the following components in parts by weight: 70 parts of herba epimedii; 40 parts of morinda officinalis; 40 parts of prepared rehmannia root; 25 parts of rhizoma polygonati; unlocking 25 parts of a gold lock; 25 parts of elaeagnus pungens leaf; 8 parts of dwarf lilyturf tuber; 8 parts of astragalus; 4 parts of radix codonopsis; 8 parts of bighead atractylodes rhizome; 4 parts of negundo chastetree fruit; 18 parts of white mulberry root-bark; 12 parts of rhizoma pinellinae praeparata; 8 parts of fingered citron; 40 parts of raw licorice.
The preparation method comprises the following steps:
(1) Mixing the above Chinese medicinal materials, adding 10 times of water, and reflux extracting at 100deg.C for 1.5 hr to obtain extractive solution;
(2) Concentrating the extractive solution under reduced pressure to remove water, and drying to obtain Chinese medicinal extract;
the water in the step (1) is an aqueous solution containing soapberry saponin and n-octyl-beta-D-glucopyranoside; wherein the mass fraction of soapberry saponin and n-octyl-beta-D-glucopyranoside in water is 0.3 percent respectively.
EXAMPLE 4 preparation of a Chinese medicinal composition
The raw materials comprise the following components in parts by weight: 70 parts of herba epimedii; 40 parts of morinda officinalis; 40 parts of prepared rehmannia root; 25 parts of rhizoma polygonati; unlocking 25 parts of a gold lock; 25 parts of elaeagnus pungens leaf; 8 parts of dwarf lilyturf tuber; 8 parts of astragalus; 4 parts of radix codonopsis; 8 parts of bighead atractylodes rhizome; 4 parts of negundo chastetree fruit; 18 parts of white mulberry root-bark; 12 parts of rhizoma pinellinae praeparata; 8 parts of fingered citron; 40 parts of raw licorice.
The preparation method comprises the following steps:
(1) Mixing the above Chinese medicinal materials, adding 10 times of water, and reflux extracting at 100deg.C for 1.5 hr to obtain extractive solution; wherein, the water in the step (1) is an aqueous solution containing soapberry saponin and n-octyl-beta-D-glucopyranoside; the mass fraction of soapberry saponin and n-octyl-beta-D-glucopyranoside in water is 0.3 percent respectively.
(2) Concentrating the extractive solution under reduced pressure to remove water, and drying to obtain medicinal liquid extract;
(3) Loading the water extract of the Chinese medicinal materials on HP-20 type macroporous resin column, eluting with 18% ethanol with volume 2 times of column volume to remove impurities; then eluting with 33% ethanol with 6 times of column volume, collecting eluate eluted with 33% ethanol, concentrating under reduced pressure, and drying to obtain the final product.
Comparative example 1 preparation of Chinese medicinal composition
The raw materials comprise the following components in parts by weight: 70 parts of herba epimedii; 40 parts of morinda officinalis; 40 parts of prepared rehmannia root; 25 parts of rhizoma polygonati; 50 parts of a golden lock is opened; 8 parts of dwarf lilyturf tuber; 8 parts of astragalus; 4 parts of radix codonopsis; 8 parts of bighead atractylodes rhizome; 4 parts of negundo chastetree fruit; 18 parts of white mulberry root-bark; 12 parts of rhizoma pinellinae praeparata; 8 parts of fingered citron; 40 parts of raw licorice.
The preparation method is the same as in example 1.
Comparative example 1 differs from examples 1 and 2 in that example 2 is a combination of a leaf of thorny elaeagnus and a leaf of thorny elaeagnus; in contrast to example 1, only the addition of the gold-locking agent to the raw materials of the Chinese medicinal composition was performed in comparison with example 1.
Comparative example 2 preparation of Chinese medicinal composition
The raw materials comprise the following components in parts by weight: 70 parts of herba epimedii; 40 parts of morinda officinalis; 40 parts of prepared rehmannia root; 25 parts of rhizoma polygonati; 50 parts of elaeagnus pungens leaf; 8 parts of dwarf lilyturf tuber; 8 parts of astragalus; 4 parts of radix codonopsis; 8 parts of bighead atractylodes rhizome; 4 parts of negundo chastetree fruit; 18 parts of white mulberry root-bark; 12 parts of rhizoma pinellinae praeparata; 8 parts of fingered citron; 40 parts of raw licorice.
The preparation method is the same as in example 1.
Comparative example 2 differs from examples 1 and 2 in that example 2 is a combination of a leaf of thorny elaeagnus and a leaf of thorny elaeagnus; in contrast, in comparative example 2, only thorny elaeagnus leaves were added to the raw materials of the Chinese medicinal composition as in example 1.
Comparative example 3 preparation of Chinese medicinal composition
The raw materials comprise the following components in parts by weight: 70 parts of herba epimedii; 40 parts of morinda officinalis; 40 parts of prepared rehmannia root; 25 parts of rhizoma polygonati; unlocking 25 parts of a gold lock; 25 parts of elaeagnus pungens leaf; 8 parts of dwarf lilyturf tuber; 8 parts of astragalus; 4 parts of radix codonopsis; 8 parts of bighead atractylodes rhizome; 4 parts of negundo chastetree fruit; 18 parts of white mulberry root-bark; 12 parts of rhizoma pinellinae praeparata; 8 parts of fingered citron; 40 parts of raw licorice.
The preparation method comprises the following steps:
(1) Mixing the above Chinese medicinal materials, adding 10 times of water, and reflux extracting at 100deg.C for 1.5 hr to obtain extractive solution; wherein, the water in the step (1) is an aqueous solution containing soapberry saponin and n-octyl-beta-D-glucopyranoside; the mass fraction of soapberry saponin and n-octyl-beta-D-glucopyranoside in water is 0.3 percent respectively.
(2) Concentrating the extractive solution under reduced pressure to remove water, and drying to obtain medicinal liquid extract;
(3) Loading the water extract of the Chinese medicinal materials on HP-20 type macroporous resin column, eluting with 2 times of column volume water to remove impurities; then eluting with 20% ethanol with 6 times of column volume, collecting eluate eluted with 20% ethanol, concentrating under reduced pressure, and drying to obtain the final product.
Comparative example 3 differs from example 4 in that the conditions for elution of the macroporous resin column are different, and comparative example 3 is eluted with water to remove impurities, followed by elution with 20% ethanol; in example 4, the impurities were removed by eluting with 18% ethanol, followed by eluting with 33% ethanol.
Comparative example 4 preparation of Chinese medicinal composition
The raw materials comprise the following components in parts by weight: 70 parts of herba epimedii; 40 parts of morinda officinalis; 40 parts of prepared rehmannia root; 25 parts of rhizoma polygonati; unlocking 25 parts of a gold lock; 25 parts of elaeagnus pungens leaf; 8 parts of dwarf lilyturf tuber; 8 parts of astragalus; 4 parts of radix codonopsis; 8 parts of bighead atractylodes rhizome; 4 parts of negundo chastetree fruit; 18 parts of white mulberry root-bark; 12 parts of rhizoma pinellinae praeparata; 8 parts of fingered citron; 40 parts of raw licorice.
The preparation method comprises the following steps:
(1) Mixing the above Chinese medicinal materials, adding 10 times of water, and reflux extracting at 100deg.C for 1.5 hr to obtain extractive solution; wherein, the water in the step (1) is an aqueous solution containing soapberry saponin and n-octyl-beta-D-glucopyranoside; the mass fraction of soapberry saponin and n-octyl-beta-D-glucopyranoside in water is 0.3 percent respectively.
(2) Concentrating the extractive solution under reduced pressure to remove water, and drying to obtain medicinal liquid extract;
(3) Loading the water extract of the Chinese medicinal materials on HP-20 type macroporous resin column, eluting with 30% ethanol with volume 2 times of column volume to remove impurities; then eluting with 60% ethanol with 6 times of column volume, collecting eluate eluted with 60% ethanol, concentrating under reduced pressure, and drying to obtain the final product.
Comparative example 4 differs from example 4 in that the conditions for elution of the macroporous resin column are different, and comparative example 4 is eluted with 30% ethanol to remove impurities, followed by eluting with 60% ethanol; in example 4, the impurities were removed by eluting with 18% ethanol, followed by eluting with 33% ethanol.
Experimental example 1
Modeling method of asthma model rats: SD rats with the weight of 200+/-20 g are selected, and male and female halves are selected; physiological saline containing ovalbumin (10 mg) and aluminum hydroxide dry powder (100 mg) was intraperitoneally injected every day 3 days before each rat; after 7 days of feeding, physiological saline containing ovalbumin (10 mg) and aluminum hydroxide dry powder (100 mg) was injected again 1 time on day 8; after 14 days of continuous feeding, the rats were placed in an environment containing ultrasonically atomized ovalbumin for 30min for the purpose of stimulating asthma in the rats; rats with asthma-like attacks were selected as asthma model rats 1 time a day in the morning and evening, 2 weeks after the continuous period.
90 Asthma model rats constructed according to the modeling method are randomly divided into 9 groups, namely, male and female halves, and 10 rats in each group, wherein the groups are divided into experimental groups 1-8 and model groups; 10 SD rats with a weight of 200+ -20 g were selected as normal control groups.
The traditional Chinese medicine compositions prepared in examples 1 to 4 and comparative examples 1 to 4 are infused to the stomach at a dosage of 100mg/kg every day in experimental groups 1 to 8; the model group and the normal control group were perfused with an equal amount of physiological saline. Counting the respiratory rate of each group of rats after 2 weeks of continuous gastric lavage administration; the statistical results are shown in Table 1.
Table 1.
| Group of | Test sample | Respiratory rate (times/min) |
| Normal control group | - | 133±17 |
| Model group | - | 259±39 |
| Experiment group 1 | The Chinese medicinal composition prepared in example 1 | 233±34 |
| Experiment group 2 | The Chinese medicinal composition prepared in example 2 | 195±27 |
| Experiment group 3 | The Chinese medicinal composition prepared in example 3 | 181±23 |
| Experiment group 4 | The Chinese medicinal composition prepared in example 4 | 142±19 |
| Experiment group 5 | Traditional Chinese medicine composition prepared in comparative example 1 | 228±32 |
| Experiment group 6 | Traditional Chinese medicine composition prepared in comparative example 2 | 222±31 |
| Experiment group 7 | Traditional Chinese medicine composition prepared in comparative example 3 | 189±26 |
| Experiment group 8 | Traditional Chinese medicine composition prepared in comparative example 4 | 176±23 |
As can be seen from the experimental data in table 1, the respiratory rate of rats in the model group is significantly higher than that of rats in the normal control group; this indicated that the asthma model rats were successfully constructed.
As can be seen from the experimental data in table 1, the respiratory rate of rats in experimental group 1 was significantly lower than that of rats in the model group; this illustrates: the traditional Chinese medicine composition prepared from the traditional Chinese medicine raw material components has better function of preventing and treating asthma.
As can be seen from the experimental data in table 1, the respiratory rate of rats in experimental group 2 was significantly lower than that in experimental group 1 and significantly lower than that in the model group; this illustrates: the invention further adds the radix cynanchi wilfordii and the elaeagnus pungens to the raw materials of the traditional Chinese medicine composition comprising the epimedium herb, the morinda officinalis, the prepared rehmannia root, the rhizoma polygonati, the dwarf lilyturf tuber, the astragalus root, the codonopsis pilosula, the bighead atractylodes rhizome, the negundo chastetree fruit, the white mulberry root-bark, the prepared pinellia tuber, the fingered citron and the raw liquorice, thereby remarkably improving the asthma treatment effect of the prepared traditional Chinese medicine composition. Whereas the respiratory rate of rats in experimental groups 5 and 6 was not significantly lower than that of experimental group 1, compared to example 1, the reduction was significantly less than that of experimental group 2; this illustrates: the traditional Chinese medicine composition containing epimedium herb, morinda officinalis, prepared rehmannia root, rhizoma polygonati, dwarf lilyturf tuber, astragalus root, dangshen, bighead atractylodes rhizome, negundo chastetree fruit, white mulberry root-bark, prepared pinellia tuber, fingered citron and raw liquorice is only added with the Chinese medicinal composition raw materials of the Chinese medicinal composition, so that the asthma treatment effect of the prepared traditional Chinese medicine composition can not be obviously improved; only if the leaf of the Elaeagnus pungens and the leaf of the Elaeagnus pungens are further added into the raw materials of the traditional Chinese medicine composition, the asthma treatment effect of the prepared traditional Chinese medicine composition can be obviously improved.
As can be seen from the experimental data in table 1, rats in experimental group 3 had a lower respiratory rate than rats in experimental group 2; this illustrates: the Chinese medicinal composition prepared by extracting the soapberry saponin and the n-octyl-beta-D-glucopyranoside in the aqueous solution can further improve the asthma treatment effect of the prepared Chinese medicinal composition compared with the Chinese medicinal composition prepared by simply extracting with water.
As can be seen from the experimental data in table 1, the respiratory rate of rats in experimental group 4 was further significantly lower than that of rats in experimental group 3, much lower than that of the model group, and similar to that of the normal control group. This illustrates: the traditional Chinese medicine water extract is further subjected to macroporous resin column chromatography to prepare the traditional Chinese medicine composition, so that the effect of treating asthma is further greatly improved; has excellent asthma treating effect.
As can be seen from the experimental data in table 1, the respiratory rate of rats in experimental groups 7 and 8 was not reduced or significantly reduced compared to experimental group 3; the respiratory rate is greatly higher than that of the experimental group 4; this illustrates: in the process of preparing the traditional Chinese medicine composition by further adopting the perforated resin, the elution condition of the macroporous resin is very critical; the Chinese medicinal composition prepared by eluting the Chinese medicinal water extract with 18% ethanol to remove impurities and then with 33% ethanol has a greatly improved asthma treating effect compared with the Chinese medicinal water extract; however, the effect of treating asthma of the traditional Chinese medicine composition prepared under the condition of eluting other macroporous resin cannot be further improved greatly.
Claims (7)
1. A traditional Chinese medicine composition with an effect of preventing and/or treating asthma is characterized by being prepared from the following raw materials in parts by weight: 50-80 parts of herba epimedii; 30-50 parts of morinda officinalis; 30-50 parts of prepared rehmannia root; 20-30 parts of rhizoma polygonati; 5-10 parts of dwarf lilyturf tuber; 5-10 parts of astragalus; 3-5 parts of codonopsis pilosula; 5-10 parts of bighead atractylodes rhizome; 3-5 parts of negundo chastetree fruit; 15-20 parts of white mulberry root-bark; 10-15 parts of rhizoma pinellinae praeparata; 5-10 parts of fingered citron; 30-50 parts of raw licorice; unlocking 20-30 parts of a gold lock; 20-30 parts of elaeagnus pungens leaves;
The preparation method of the traditional Chinese medicine composition comprises the following steps:
(1) Mixing the Chinese medicinal materials, adding water, and heating to extract to obtain extractive solution;
(2) Concentrating the extractive solution under reduced pressure to remove water, and drying to obtain medicinal liquid extract;
Loading the water extract of the Chinese medicinal materials into macroporous resin column, eluting with 18% ethanol with volume 2 times of column volume to remove impurities; then eluting with 33% ethanol with 6 times of column volume, collecting eluate eluted with 33% ethanol, concentrating under reduced pressure, and drying to obtain the Chinese medicinal composition;
wherein, the water in the step (1) is an aqueous solution containing soapberry saponin and n-octyl-beta-D-glucopyranoside; the mass fraction of soapberry saponin and n-octyl-beta-D-glucopyranoside in water is 0.3 percent respectively.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 60-70 parts of herba epimedii; 40-50 parts of morinda officinalis; 40-50 parts of prepared rehmannia root; 25-30 parts of rhizoma polygonati; 8-10 parts of dwarf lilyturf tuber; 5-8 parts of astragalus; 3-4 parts of radix codonopsis; 5-8 parts of bighead atractylodes rhizome; 4-5 parts of negundo chastetree fruit; 15-18 parts of white mulberry root-bark; 10-12 parts of rhizoma pinellinae praeparata; 5-8 parts of fingered citron; 40-50 parts of raw licorice.
3. The traditional Chinese medicine composition according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 70 parts of herba epimedii; 40 parts of morinda officinalis; 40 parts of prepared rehmannia root; 25 parts of rhizoma polygonati; 8 parts of dwarf lilyturf tuber; 8 parts of astragalus; 4 parts of radix codonopsis; 8 parts of bighead atractylodes rhizome; 4 parts of negundo chastetree fruit; 18 parts of white mulberry root-bark; 12 parts of rhizoma pinellinae praeparata; 8 parts of fingered citron; 40 parts of raw licorice.
4. The traditional Chinese medicine composition according to claim 1, wherein the parts by weight of the leaf of elaeagnus pungens and the leaf of elaeagnus pungens in the composition are respectively: unlocking 25 parts of a gold lock; 25 parts of elaeagnus pungens leaf.
5. The Chinese medicinal composition according to claim 1, wherein the extraction in the step (1) is performed at 80-100 ℃ for 1-2 hours.
6. The use of the Chinese medicinal composition according to any one of claims 1 to 4 in the preparation of a medicament for preventing and/or treating asthma.
7. The use according to claim 6, wherein the medicament is in the form of granules, sprays, oral liquids, powders, tablets or capsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211594355.9A CN115814022B (en) | 2022-12-13 | Traditional Chinese medicine composition, preparation method thereof and application thereof in preparation of medicine with function of preventing and/or treating asthma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211594355.9A CN115814022B (en) | 2022-12-13 | Traditional Chinese medicine composition, preparation method thereof and application thereof in preparation of medicine with function of preventing and/or treating asthma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115814022A CN115814022A (en) | 2023-03-21 |
| CN115814022B true CN115814022B (en) | 2024-07-02 |
Family
ID=
Non-Patent Citations (2)
| Title |
|---|
| 玉屏风散加减治疗小儿支气管哮喘临床研究;王文亮;;中国当代医药;17(18);第93页左栏第1, 3段 * |
| 补肾平喘膏方对支气管哮喘大鼠肺组织糖皮质激素受体的影响;石克华;吴银根;熊必丹;喻晓;;中西医结合学报;8(08);第786页左栏第1，3段以及第798页左栏第1段 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112972547B (en) | Traditional Chinese medicine composition for treating qi and blood deficiency syndrome and preparation method and application thereof | |
| CN101433701B (en) | Chinese medicament preparation for treating children's anorexia and preparation method | |
| WO2009015557A1 (en) | A pharmaceutical composition for treating diabetes and its process for preparation | |
| CN105535448B (en) | Traditional Chinese medicine composition for treating children myasthenia gravis | |
| CN105012452A (en) | New application of clausena lansium leaves | |
| CN102302673B (en) | Traditional Chinese medicine compound preparation for preventing and treating diabetic nephropathy (DN) | |
| CN113262268A (en) | Traditional Chinese medicine composition for clearing lung and eliminating phlegm and application thereof in treating lung diseases | |
| CN115814022B (en) | Traditional Chinese medicine composition, preparation method thereof and application thereof in preparation of medicine with function of preventing and/or treating asthma | |
| CN107569528B (en) | Pharmaceutical composition for treating hepatitis, pharmaceutical preparation, application and preparation method | |
| CN100569263C (en) | A kind of pharmaceutical composition for the treatment of stomachache and preparation method thereof | |
| CN114099609B (en) | Pharmaceutical composition for treating cough and preparation method thereof | |
| CN115814022A (en) | Traditional Chinese medicine composition, preparation method thereof and application thereof in preparation of medicine with asthma prevention and/or treatment effects | |
| CN110652590B (en) | Traditional Chinese medicine compound for treating diabetes and preparation method and application thereof | |
| CN104547683B (en) | A kind of Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| CN102755519B (en) | Kudzuvine root-kudzuvine flower anti-canker sore particle and preparation method thereof | |
| CN105288128A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparing method thereof | |
| CN109432193B (en) | Pharmaceutical composition for treating cough and preparation method thereof | |
| CN116920061B (en) | Traditional Chinese medicine composition for treating hyperglycemia and preparation method thereof | |
| CN109364206A (en) | The preparation method and applications of Xingbei Zhike granules active site | |
| CN116889269B (en) | Chinese medicinal solid beverage for improving immunity of human body | |
| CN113181259B (en) | Children's astragalus-ginseng cold-treating granule and its prepn | |
| CN108143905A (en) | It is a kind of to be used to treat compound medicine of chronic bronchitis and preparation method thereof | |
| CN114796432B (en) | Traditional Chinese medicine composition for treating gastritis and preparation method thereof | |
| CN115501293B (en) | Preparation method of blood glucose reducing composition containing prepared rehmannia root, chinese yam and kudzuvine root | |
| CN1124634A (en) | Antitussive Chinese drug and preparing process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |